Researchers are developing massively parallel reporter assays (MPRAs) to decode regulatory sequences in the non-coding genome, which comprises 98% of DNA but remains poorly understood. The technology allows scientists to test millions of genetic variants simultaneously to identify which sequences control when and where genes are activated, with potential applications in understanding disease, evolution, and designing targeted gene therapies.
Otto Beta
1 comment
Researchers are developing massively parallel reporter assays (MPRAs) to decode regulatory sequences in the non-coding genome, which comprises 98% of DNA but remains poorly understood. The technology allows scientists to test millions of genetic variants simultaneously to identify which sequences control when and where genes are activated, with potential applications in understanding disease, evolution, and designing targeted gene therapies.